Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

16260 Ventura Blvd., Suite 140
Encino, CA 91436
Phone: 818-528-7776

June 13, 2019 by Alan Khadavi

Dupixent for Hives

Dupixent for hives is novel treatment option for patients with difficult to treatment chronic spontaneous urticaria.  Chronic hives is a common condition marked by episodes of elevated, itching, red wheals persisting for more than 6 weeks without a specific known cause.  It is estimated that chronic hives affects about 1% of the population.

The mechanism of action of chronic hives is not well understood, however it is rooted in mast cell activation and degranulation.  Many treatments exist for chronic spontaneous urticaria, although they may not be effective in all cases.

Stepwise approach to Chronic Urticaria (Chronic Hives)

Xolair is a monoclonal antibody that is effective but not in all cases.

FDA approves Xolair for Chronic Urticaria

Some studies reported it is not effective in up to 1/3 of cases.  Cyclosporine is also effective, but many patients are hesitant to use it because of reported side effects and monitoring.

Severe Hives Treatment (Xolair and Cyclosporine)

A recent study published in the Journal of Allergy and Clinical Immunology, titled “Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria” looked at to see if Dupixent was a reasonable therapy for Omalizumab (Xolair) treatment failures.

Currently dupilumab is approved for moderate to severe atopic dermatitis and moderate to severe asthma.

Dupilumab (Dupixent) for Atopic Dermatitis (Eczema) Sufferers

Dupilumab for Asthma, a New Indication

And other indications may be coming. Dupilumab for Nasal Polyps

In the study published, 6 patients who failed Xolair for chronic hives were treated with Dupixent of up to 600mg monthly, who responded to it.  This may point to a mechanism of involving IL-4 and IL-13.  Thy may occur from IL-4 blocking the induction of B cell to plasma cell subclass switching from IgM to IgE as well as limiting the IL-13 inflammatory cascade that leads to itching in eczema and hives.

This report strongly suggests that Dupixent for hives has a potential role in chronic idiopathic urticaria and it warrants further studies.

Filed Under: biologics, Blog, hives, Urticaria

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

January 22, 2023

Is Benadryl Safe to use, or is it Time to Move on?

is benadryl safe

January 12, 2023

Airsupra for Asthma, a new rescue medication

airsupra

December 26, 2022

Cantaloupe Allergy comes in many flavors

cantaloupe allergy

December 23, 2022

Remibrutinib, a BTK inhibitor for Chronic Hives

remibrutininb

November 21, 2022

Eczema and Hard Water, is there a link?

eczema and hard water

November 19, 2022

Nucala, Fasenra or Dupixent for Severe Eosinophilic Asthma?

nucala fasenra dupixent

November 18, 2022

Xolair for idiopathic angioedema

xolair for idiopathic angioedema

September 29, 2022

When will my child outgrow egg allergy?

outgrow egg allergy

September 13, 2022

Can you be allergic to water? (Aquagenic Urticaria)

allergic to water

September 8, 2022

Oclacitinib for Atopic Dermatitis (Eczema) in Dogs

oclacitinib

Read More Posts...

Follow Us…

© 2023 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page